INTRODUCTION:
Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors and account for less than 1% of all gastrointestinal tumors. Approximately 90% of cases originate in the stomach and small intestine (1) . They have a wide clinical spectrum ranging from benign incidentally detected nodules to large malignant tumors and must be distinguished from other mesenchymal tumors (2) . Their origin was initially attributed to Cajal's cells but it has recently been supposed that they originate from multi potential mesenchymal stem cells, which could explain their resistance to chemotherapy.
. These cells have been
shown to express the cell surface receptor C-kit, which is identified by CD117. C-kit functions as a tyrosine kinase, which is activated as a ligand in the presence of a stem cell factor. (4) A mutation of the Ckit proto-oncogene that activates tyrosine kinase in the absence of a stem cell factor, leading to uncontrolled cell proliferation.
So therapy with a tyrosine kinase inhibitor (TKI) shows an impressive response.
. It usually occurs in middle aged and older patients (fifth to seventh decades, with no specific sex predominance.
. Surgery is the mainstay of therapy for non-metastatic
GISTs. Laparoscopic surgery has been shown to be effective for removal of these tumors without the need of large incisions (6) . Tumors are usually resistant to conventional cytotoxic-chemotherapy and radiation (7) . The c-kit tyrosine kinase inhibitor Imatinib (Glivec/Gleevec), a drug initially marked for chronic myelogenous leukemia, was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases.
.The current response evaluation criteria in solid tumors are based on unidimensional tumor size, and do not take into account changes in responding GISTs such as a decrease in tumor density and decrease in the number of intratumoral vessels with computed tomography (CT).
Modified CT criteria using a combination of tumor density and tumor size are promising in early response evaluation, and have excellent prognostic value (9) .
Positron emission tomography (PET) has been found to be highly sensitive in assessment early response to Imatinib mesylate. Also, it is useful in predicting long-term response to imatinib in patients with metastatic GIST; however, widespread use of PET is limited because of cost constrains (10) . We retrospectively compared the performance and prognostic impact of 18F-FDG PET/CT and diagnostic CT in staging and evaluating 
RESULTS:
Consecutive patients with histologically (11) . There is now convincing evidence that serial PET study is more sensitive and reliable for determining treatment response to Imatinib mesylate in patients of GIST, when compared with only conventional CT monitoring. (11) . Traditional tumor response criteria such as RECIST are based on unidimensional tumor size and do not take into account changes in tumor metabolism, tumor density, and decrease in the number of intra-tumoral vessels. All of these changes indicate response to TKI therapy in patients with GIST. Hence, response assessment according to RECIST is known to be insensitive in evaluating response to TKI therapy (11) . However, these patients are most likely responding to the treatment (15) . This phenomenon was observed by Joensuu et al. (16) , they stated that some lesions can be isodense to the hepatic parenchyma prior to therapy and may not be seen on (19) .Their results showed that nodal metastasis had no prognostic significance for overall and disease free survival (p = 0.65 and p = 0.57, respectively). Prakash et al. (20, 21) in a review on 15 patients with GIST 
